Pharmaceutical composition for treatment or prevention of obesity-related hypertension and usage of pharmaceutical composition for treatment or prevention of obesity-related hypertension

A technology for obesity-type hypertension and a composition, applied in the field of western medicine compound prescriptions, can solve the problems of poor effect, unable to satisfy patients, unable to reduce blood pressure, unsatisfactory effect of weight loss, etc. The effect of blood pressure

Inactive Publication Date: 2016-01-13
QINGDAO YUNTIAN BIOTECH
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are a variety of treatment methods. For example, many obese patients with high blood pressure try to lose weight and lower blood pressure by taking weight-loss drugs. However, the efficacy of weight loss is very unsatisfactory, and blood pressure cannot be lowered. Poor, which ultimately leads to poor results and cannot meet the needs of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treatment or prevention of obesity-related hypertension and usage of pharmaceutical composition for treatment or prevention of obesity-related hypertension
  • Pharmaceutical composition for treatment or prevention of obesity-related hypertension and usage of pharmaceutical composition for treatment or prevention of obesity-related hypertension
  • Pharmaceutical composition for treatment or prevention of obesity-related hypertension and usage of pharmaceutical composition for treatment or prevention of obesity-related hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1: the prescription of the compound tablet of captopril / orlistat: (1000)

[0024]

[0025]

[0026] Weigh orlistat and captopril according to the prescription, use microcrystalline cellulose as filler, croscarmellose sodium and polyvinylpyrrolidone as disintegrant, and 5% PVP60% ethanol solution as binder , sodium stearate fumarate as a lubricant, one-step granulation in a fluidized bed, and then compressed into tablets.

Embodiment 2

[0027] Embodiment 2: the prescription of the compound tablet of captopril / orlistat: (1000)

[0028]

[0029] Preparation Process:

[0030] Weigh orlistat and captopril according to the prescription, use microcrystalline cellulose as filler, croscarmellose sodium and polyvinylpyrrolidone as disintegrant, and 5% PVP60% ethanol solution as binder , sodium stearate fumarate as a lubricant, one-step granulation in a fluidized bed, and then compressed into tablets.

Embodiment 3

[0031] Embodiment 3: the prescription of the compound tablet of captopril / orlistat: (1000)

[0032]

[0033] Preparation Process:

[0034] Weigh orlistat and captopril according to the prescription, use microcrystalline cellulose as filler, croscarmellose sodium and polyvinylpyrrolidone as disintegrant, and 5% PVP60% ethanol solution as binder , sodium stearate fumarate as a lubricant, one-step granulation in a fluidized bed, and then compressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines and discloses a pharmaceutical composition for treatment or prevention of obesity-related hypertension. The pharmaceutical composition comprises active ingredients of orlistat and angiotensin converting enzyme inhibitors, and risks of physical damages are reduced since consumption of the orlistat and angiotensin converting enzyme inhibitors in the pharmaceutical composition is greatly reduced. The pharmaceutical composition has a remarkable synergistic effect in treatment or prevention of obesity-related hypertension, is capable of reducing weights of obese patients and risks of hypertension and cardiavascular diseases and has a promising medical application prospect.

Description

technical field [0001] The invention relates to a western medicine compound, in particular to a pharmaceutical composition for treating obese hypertension and its application, and belongs to the technical field of western medicine compound. Background technique [0002] Obesity has become a mainstream trend in today's society. Due to the continuous improvement of people's living standards in recent years, more and more people have stepped into the ranks of obesity. Obesity, especially abdominal obesity, in addition to abnormal sugar and fat metabolism, will also increase the release of certain inflammatory factors, making the body in a state of inflammatory response for a long time. In addition to causing the above-mentioned metabolic syndrome, it can also greatly contribute to vascular endothelial damage, atherosclerosis, thrombosis, heart damage, etc. Furthermore, it increases the possibility of a large number of cardiovascular and cerebrovascular diseases such as hyperte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K38/05A61K31/55A61K31/401A61P9/12A61P3/04A61K31/365
Inventor 不公告发明人
Owner QINGDAO YUNTIAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap